Study Treatment
toxicities, death, nasopharyngeal necrosis
DISEASE PROGRESSION, BLEEDING
Apatinib 250 mg was administered orally once daily and camrelizumab 200 mg was administered intravenously once every 3 weeks, until disease progression, death, unacceptable toxicities, or at the patient's request.Dose modifications of camrelizumab were not permitted. Dose interruptions and reductions (1-2 times) of apatinib were permitted for toxicities that were not relieved by supportive care, with a first dose reduction to 250 mg for 5 days on-2 days off and a second reduction to 250 mg every other day. In cases of high-risk major bleeding (such as nasopharyngeal necrosis invading the internal carotid artery [ICA]) assessed by the investigator, apatinib administration was discontinued. Details of dose modifications and supportive measures are provided in the protocol.